查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2058348

全球醫藥供應鏈人工智慧市場：按組件、技術、供應鏈階段、部署模式、最終用戶和地區分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Global AI in Pharma Supply Chain Market: By Component, Technology, Supply Chain Stage, Deployment, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球醫藥供應鏈人工智慧市場正經歷來自全球醫療保健產業的顯著且加速成長的需求。預計到2025年，該市場規模將達到約28.8億美元，反映出人工智慧作為提升供應鏈效率和韌性的策略要素正日益受到認可。隨著全球醫藥網路日益複雜，各公司正積極投資智慧技術，以實現營運現代化並提高階到端的可視性。預計這一強勁成長動能將在未來十年持續，到2035年，市場規模預計將達到約250.5億美元，在2026年至2035年的預測期內，年複合成長率將高達24.15%。

推動這一快速成長的主要因素是迫切需要減少與藥品浪費和供不應求相關的巨大經濟損失。每年，製藥公司和醫療系統因庫存過期、儲存條件不當、需求預測不準確以及配送效率低下而損失數十億美元。同時，關鍵藥物的短缺嚴重影響患者照護，可能導致治療延誤和健康惡化。這些挑戰凸顯了傳統供應鏈管理方法的局限性，並正在加速人工智慧解決方案的普及應用。

顯著的市場趨勢

全球醫藥供應鏈人工智慧市場較為分散，競爭也異常激烈。該市場既有全球超大規模資料中心業者企業，也有專注於供應鏈解決方案供應商。微軟憑藉其龐大的Azure雲端基礎設施，在該市場佔據主導地位。 IBM則透過其以Watson為基礎的先進分析平台，不斷增強自身競爭力。

亞馬遜雲端服務 (AWS) 在確保關鍵製藥應用的高可用性和可擴展性方面發揮著至關重要的作用。 Oracle 憑藉其根深蒂固的企業資料庫和資源規劃系統，保持強大的市場地位。 Oracle透過提供專為製藥需求量身定做的專業物流和供應鏈模組，佔據了相當大的市場佔有率。

主要成長要素

全球醫藥供應鏈人工智慧市場正經歷著強勁且不斷成長的需求，這主要得益於全球醫療保健生態系統對藥品生產和分銷網路效率、透明度和韌性的日益成長的需求。隨著全球醫藥營運日益複雜化和互聯互通，各組織面臨越來越大的壓力，需要利用先進的數位技術來提升其供應鏈能力。人工智慧正成為這項變革的關鍵驅動力，幫助價值鏈上的所有相關人員應對不確定性、減少低效環節，並確保基本藥物的及時供應。

新機會的趨勢

全球醫藥供應鏈人工智慧市場正日益受到高精度預測分析技術應用的推動，這項技術正成為提升效率和降低營運成本的核心功能。隨著醫藥供應鏈日益複雜化和全球化，企業正利用智慧系統預測需求模式、最佳化資源配置，並最大限度地減少價值鏈各環節的低效率環節。這種向數據驅動決策的轉變，使企業能夠擺脫被動的規劃模式，轉向更主動、基於預測的策略。

最佳化障礙

監管和合規方面的障礙預計將顯著限制全球人工智慧市場在醫藥供應鏈中的成長。醫藥產業在全球最嚴格的法規結構之一下運作，該框架要求在整個生產、分銷和品質保證過程中都必須遵守藥品生產品質管理規範 (GxP) 指南。這些法規旨在確保藥品生命週期的每個階段都可控、可記錄和檢驗，從而最大限度地減少不確定性或未經記錄的決策。

目錄

第1章執行摘要：全球醫藥供應鏈中的人工智慧市場

第2章：報告概述

  • 研究框架
    • 研究目標
    • 市場的定義
    • 市場區隔
  • 調查方法
    • 市場規模估算
    • 定性研究
      • 一手和二手資訊
    • 量化研究
      • 一手和二手資訊
    • 主要調查受訪者組成：按地區分類
    • 數據三角測量
    • 本研究的前提

第3章：全球醫藥供應鏈中的人工智慧市場概述

  • 產業價值鏈分析
  • 產業展望
    • 醫學藥物流數位化
    • 人們越來越關注需求預測和藥品短缺預測。
    • 關於序列化、可追溯性和防偽的法規
    • 擴大低溫運輸，直接向患者運送藥品。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
  • 市場吸引力分析
    • 按組件
  • 可執行的見解（分析師建議）

第4章：競爭對手儀錶板

  • 市場集中度
  • 企業市場占有率分析，2025 年
  • 競爭對手分析與基準測試

第5章：全球醫藥供應鏈中的人工智慧市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 按組件
      • 關鍵見解
        • 軟體
        • 服務
    • 透過技術
      • 關鍵見解
        • 機器學習
        • 深度學習
        • 預測分析
        • 自然語言處理
        • 電腦視覺
        • 人工智慧世代
    • 供應鏈各階段
      • 關鍵見解
        • 採購與尋源
        • 製造營運
        • 庫存和倉庫管理
        • 運輸/配送
        • 低溫運輸管理
        • 商業供應計劃
    • 不同的發展
      • 關鍵見解
        • 基於雲端的
        • 現場
        • 混合
    • 最終用戶
      • 關鍵見解
        • 製藥公司
        • 生技公司
        • CDMO／CMO
        • 藥品批發商
        • 物流和低溫運輸供應商
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美醫藥供應鏈中的人工智慧市場分析

第7章：歐洲醫藥供應鏈中的人工智慧市場分析

第8章：亞太醫藥供應鏈人工智慧市場分析

第9章：中東和非洲醫藥供應鏈中的人工智慧市場分析

第10章：人工智慧在南美醫藥供應鏈中的市場分析

第11章：公司簡介

  • Accenture
  • Amazon Web Services
  • Blue Yonder
  • Deloitte
  • Google Cloud
  • IBM
  • Infor
  • Kinaxis
  • Logility
  • Microsoft
  • o9 Solutions
  • Oracle
  • project44
  • SAP
  • TCS
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA06261814

The AI in pharmaceutical supply chain market is experiencing substantial and accelerating demand across the global healthcare landscape. In 2025, the market is valued at approximately USD 2.88 billion, reflecting the growing recognition of artificial intelligence as a strategic enabler of supply chain efficiency and resilience. As pharmaceutical networks become increasingly globalized and complex, companies are investing heavily in intelligent technologies to modernize operations and improve end-to-end visibility. This strong momentum is expected to continue over the coming decade, with the market projected to reach approximately USD 25.05 billion by 2035, expanding at a remarkable compound annual growth rate (CAGR) of 24.15% during the forecast period from 2026 to 2035.

A primary driver of this rapid growth is the urgent need to reduce the significant financial losses associated with drug waste and supply shortages. Each year, pharmaceutical companies and healthcare systems collectively lose billions of dollars due to expired inventory, improper storage conditions, inaccurate demand forecasting, and distribution inefficiencies. At the same time, shortages of critical medications can have severe consequences for patient care, leading to treatment delays and compromised health outcomes. These challenges have highlighted the limitations of traditional supply chain management approaches and accelerated the adoption of AI-powered solutions.

Noteworthy Market Developments

The AI in pharmaceutical supply chain market is moderately fragmented and highly competitive, characterized by the presence of both global technology hyperscalers and specialized supply chain solution providers. Microsoft holds a dominant position in the market by leveraging its expansive Azure cloud infrastructure. IBM strengthens its competitive position through its advanced analytics platform powered by Watson.

Amazon Web Services (AWS) plays a crucial role in ensuring high availability and scalability for critical pharmaceutical applications. Oracle Corporation maintains a strong foothold in the market through its deeply entrenched enterprise database and resource planning systems. SAP commands a significant share of the market by offering specialized logistics and supply chain modules tailored to pharmaceutical requirements.

Core Growth Drivers

The AI in pharmaceutical supply chain market is witnessing strong and expanding demand across global healthcare ecosystems, driven by the increasing need for efficiency, transparency, and resilience in drug production and distribution networks. As pharmaceutical operations become more complex and globally interconnected, organizations are under growing pressure to modernize their supply chain capabilities using advanced digital technologies. AI has emerged as a key enabler in this transformation, helping stakeholders across the value chain manage uncertainty, reduce inefficiencies, and ensure the timely availability of essential medicines.

Emerging Opportunity Trends

The AI in pharmaceutical supply chain market is increasingly driven by the adoption of highly accurate predictive analytics, which has become a core capability for improving efficiency and reducing operational costs. As pharmaceutical supply chains grow more complex and globally distributed, organizations are relying on intelligent systems to anticipate demand patterns, optimize resource allocation, and minimize inefficiencies across multiple stages of the value chain. This shift toward data-driven decision-making is enabling companies to move away from reactive planning models and toward more proactive, forecast-based strategies.

Barriers to Optimization

Regulatory and compliance hurdles are expected to act as a significant restraint on the growth of AI in pharmaceutical supply chain market. The pharmaceutical industry operates under some of the most stringent regulatory frameworks in the world, where adherence to Good Practice (GxP) guidelines is mandatory across manufacturing, distribution, and quality assurance processes. These regulations are designed to ensure that every stage of the pharmaceutical lifecycle is controlled, documented, and verifiable, leaving little room for uncertainty or undocumented decision-making.

Detailed Market Segmentation

By technology, machine learning held a leading position in 2025, accounting for a substantial share of approximately 30%. This dominance reflects the increasing reliance on advanced data-driven systems to manage the complexity and uncertainty inherent in global pharmaceutical supply networks. As supply chains become more interconnected and data-intensive, machine learning has emerged as a foundational technology enabling organizations to extract meaningful insights from large and diverse datasets.

By supply chain stage, demand forecasting held the leading position in the AI in pharmaceutical supply chain market in 2025, accounting for a significant share of approximately 24%. This dominance reflects the increasing importance of accurately anticipating medication requirements in a highly complex and volatile healthcare environment. Pharmaceutical supply chains operate under strict constraints where both shortages and overstock situations can have serious consequences, ranging from patient treatment delays to substantial financial losses and inventory inefficiencies.

By deployment, cloud-based architectures clearly dominated the AI in pharmaceutical supply chain market in 2025, accounting for an overwhelming share of approximately 72%. This strong preference for cloud deployment reflects a broader structural shift within the pharmaceutical and life sciences industries toward more flexible, scalable, and interconnected digital ecosystems. As supply chains become increasingly global and data-intensive, organizations are prioritizing platforms that enable seamless access to real-time information across geographically dispersed operations.

By end user, pharmaceutical manufacturers led the adoption of AI in the pharmaceutical supply chain market, accounting for a dominant share of approximately 45% in 2025. This leading position reflects the central role manufacturers play in ensuring the continuous production and distribution of essential medicines across global markets. Their operations are highly sensitive to disruptions, as even minor delays in raw material procurement or logistics can immediately halt manufacturing cycles and impact downstream supply availability. Given these high operational stakes, pharmaceutical manufacturers have become the primary drivers of investment in advanced AI-enabled supply chain solutions.

Segment Breakdown

By Component

  • Software
  • Services

By Technology

  • Machine Learning
  • Deep Learning
  • Predictive Analytics
  • Natural Language Processing
  • Computer Vision
  • Generative AI

By Supply Chain Stage

  • Procurement & Sourcing
  • Manufacturing Operations
  • Inventory & Warehouse Management
  • Transportation & Distribution
  • Cold Chain Management
  • Commercial Supply Planning

By Deployment

  • Cloud-Based
  • On-Premise
  • Hybrid

By End User

  • Pharmaceutical Manufacturers
  • Biotechnology Companies
  • CDMOs/CMOs
  • Pharmaceutical Distributors
  • Logistics & Cold Chain Providers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America accounted for the largest share of the AI in pharmaceutical supply chain market in 2025, representing approximately 42% of the global total. This dominant position reflects the region's early and extensive adoption of advanced digital technologies within healthcare and life sciences logistics. The maturity of its pharmaceutical ecosystem, combined with strong investments in artificial intelligence, data analytics, and automation, has enabled North America to establish a highly efficient and technology-driven supply chain infrastructure.
  • The United States was the primary driver of this regional leadership, largely due to aggressive and sustained investments in digital transformation across the pharmaceutical sector. Major American pharmaceutical manufacturers have increasingly integrated predictive algorithms into their supply chain operations to enhance demand forecasting, optimize inventory levels, and reduce the risk of disruptions. Canada also played a significant role in strengthening North America's dominance in this market. The country has made substantial progress in upgrading its national healthcare databases and digital health infrastructure to support more advanced tracking and data-sharing systems.

Leading Market Participants

  • Accenture
  • Amazon Web Services
  • Blue Yonder
  • Deloitte
  • Google Cloud
  • IBM
  • Infor
  • Kinaxis
  • Logility
  • Microsoft
  • o9 Solutions
  • Oracle
  • project44
  • SAP
  • TCS
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global AI in Pharma Supply Chain Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global AI in Pharma Supply Chain Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. AI Software & Platform Providers
    • 3.1.2. Data & Analytics Providers
    • 3.1.3. Cloud Infrastructure Providers
    • 3.1.4. System Integrators & Consulting Firms
    • 3.1.5. Pharmaceutical Manufacturers, Distributors & Logistics Providers
  • 3.2. Industry Outlook
    • 3.2.1. Digitalization of Pharmaceutical Logistics
    • 3.2.2. Rising Focus on Demand Sensing & Drug Shortage Prediction
    • 3.2.3. Serialization, Traceability & Anti-Counterfeiting Mandates
    • 3.2.4. Expansion of Cold Chain & Direct-to-Patient Distribution
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Component
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global AI in Pharma Supply Chain Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Component
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Software
        • 5.2.1.1.2. Services
    • 5.2.2. By Technology
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Machine Learning
        • 5.2.2.1.2. Deep Learning
        • 5.2.2.1.3. Predictive Analytics
        • 5.2.2.1.4. Natural Language Processing
        • 5.2.2.1.5. Computer Vision
        • 5.2.2.1.6. Generative AI
    • 5.2.3. By Supply Chain Stage
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Procurement & Sourcing
        • 5.2.3.1.2. Manufacturing Operations
        • 5.2.3.1.3. Inventory & Warehouse Management
        • 5.2.3.1.4. Transportation & Distribution
        • 5.2.3.1.5. Cold Chain Management
        • 5.2.3.1.6. Commercial Supply Planning
    • 5.2.4. By Deployment
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Cloud-Based
        • 5.2.4.1.2. On-Premise
        • 5.2.4.1.3. Hybrid
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Pharmaceutical Manufacturers
        • 5.2.5.1.2. Biotechnology Companies
        • 5.2.5.1.3. CDMOs/CMOs
        • 5.2.5.1.4. Pharmaceutical Distributors
        • 5.2.5.1.5. Logistics & Cold Chain Providers
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America AI in Pharma Supply Chain Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Component
    • 6.2.2. By Technology
    • 6.2.3. By Supply Chain Stage
    • 6.2.4. By Deployment
    • 6.2.5. By End User
    • 6.2.6. By Country

Chapter 7. Europe AI in Pharma Supply Chain Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Supply Chain Stage
    • 7.2.4. By Deployment
    • 7.2.5. By End User
    • 7.2.6. By Country

Chapter 8. Asia Pacific AI in Pharma Supply Chain Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Supply Chain Stage
    • 8.2.4. By Deployment
    • 8.2.5. By End User
    • 8.2.6. By Country

Chapter 9. Middle East & Africa AI in Pharma Supply Chain Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Supply Chain Stage
    • 9.2.4. By Deployment
    • 9.2.5. By End User
    • 9.2.6. By Country

Chapter 10. South America AI in Pharma Supply Chain Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Supply Chain Stage
    • 10.2.4. By Deployment
    • 10.2.5. By End User
    • 10.2.6. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Accenture
  • 11.2. Amazon Web Services
  • 11.3. Blue Yonder
  • 11.4. Deloitte
  • 11.5. Google Cloud
  • 11.6. IBM
  • 11.7. Infor
  • 11.8. Kinaxis
  • 11.9. Logility
  • 11.10. Microsoft
  • 11.11. o9 Solutions
  • 11.12. Oracle
  • 11.13. project44
  • 11.14. SAP
  • 11.15. TCS
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators